Zacks Research Analysts Cut Earnings Estimates for Repligen Co. (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN) – Research analysts at Zacks Research decreased their Q3 2024 EPS estimates for shares of Repligen in a research note issued on Tuesday, May 21st. Zacks Research analyst R. Department now anticipates that the biotechnology company will post earnings per share of $0.33 for the quarter, down from their prior estimate of $0.38. The consensus estimate for Repligen’s current full-year earnings is $1.46 per share. Zacks Research also issued estimates for Repligen’s Q1 2025 earnings at $0.44 EPS, Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.46 EPS, FY2025 earnings at $1.96 EPS, Q1 2026 earnings at $0.65 EPS and FY2026 earnings at $2.81 EPS.

A number of other equities research analysts have also recently weighed in on RGEN. JPMorgan Chase & Co. cut their price objective on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Stifel Nicolaus boosted their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Finally, KeyCorp increased their price objective on shares of Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and an average target price of $197.75.

Repligen Stock Performance

Shares of RGEN stock opened at $158.78 on Thursday. Repligen has a 12-month low of $110.45 and a 12-month high of $211.13. The firm has a market capitalization of $8.87 billion, a price-to-earnings ratio of 635.15, a price-to-earnings-growth ratio of 5.58 and a beta of 1.03. The business has a 50 day simple moving average of $174.10 and a 200 day simple moving average of $177.17. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.35 and a quick ratio of 5.24.

Repligen (NASDAQ:RGEN) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.01). The company had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. Repligen had a return on equity of 3.95% and a net margin of 2.44%. Repligen’s quarterly revenue was down 17.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.64 earnings per share.

Institutional Investors Weigh In On Repligen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Retirement Systems of Alabama increased its holdings in shares of Repligen by 0.4% in the fourth quarter. Retirement Systems of Alabama now owns 65,032 shares of the biotechnology company’s stock valued at $11,693,000 after purchasing an additional 288 shares in the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Repligen by 1.5% during the third quarter. DekaBank Deutsche Girozentrale now owns 10,457 shares of the biotechnology company’s stock worth $1,663,000 after acquiring an additional 159 shares during the last quarter. International Assets Investment Management LLC lifted its stake in shares of Repligen by 18,449.1% during the fourth quarter. International Assets Investment Management LLC now owns 58,615 shares of the biotechnology company’s stock valued at $10,539,000 after acquiring an additional 58,299 shares during the period. American Century Companies Inc. boosted its holdings in Repligen by 97.5% in the third quarter. American Century Companies Inc. now owns 217,900 shares of the biotechnology company’s stock valued at $34,648,000 after acquiring an additional 107,570 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in Repligen in the fourth quarter worth about $965,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insiders Place Their Bets

In other Repligen news, Director Karen A. Dawes sold 1,000 shares of the business’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $193.35, for a total value of $193,350.00. Following the transaction, the director now directly owns 87,367 shares in the company, valued at $16,892,409.45. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the sale, the chief executive officer now directly owns 185,249 shares in the company, valued at $36,575,562.56. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Karen A. Dawes sold 1,000 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the transaction, the director now owns 87,367 shares in the company, valued at approximately $16,892,409.45. The disclosure for this sale can be found here. Insiders sold a total of 41,296 shares of company stock worth $7,550,643 over the last quarter. Company insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.